SU1400508A3 - Способ получени производных арилтиазолов - Google Patents
Способ получени производных арилтиазолов Download PDFInfo
- Publication number
- SU1400508A3 SU1400508A3 SU864027210A SU4027210A SU1400508A3 SU 1400508 A3 SU1400508 A3 SU 1400508A3 SU 864027210 A SU864027210 A SU 864027210A SU 4027210 A SU4027210 A SU 4027210A SU 1400508 A3 SU1400508 A3 SU 1400508A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- certain
- groups
- compounds
- alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/175—Saturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Изобретение относитс к гетероциклическим соединени м, в частности к способу получени 2-(1-н-гек- сил-3-гуанидино)-4-(3-метил-, или амино-1Н-1,2,4-триазол-5-ил)тиазо- лов Cl), (II), которые могут использоватьс в медицине. Получение соединений I и II ведут из гидразида 1- -(Т-н-гексил-3-гуанидино) тиазол-4- -карбсновой кислоты и тиоацетамидом или солью 5-метш1Изотиурони при мол рном соотношении 1:55-1,5 в среде бутанола при температуре его кипени с обратным холодильником. Выход,%: т.пл. °Cj брутто фор-ла дл соединени I 39; 207-209; дл соединени II 53; 210-211; С ,. 2 табл. g С
Description
о
ел
оо
Изобретение относитс к способу получени новых химических биологиче еки активных соединений, конкретно к йпособу получени производных арил- tиaзoлoв-2-{N-замещенных гуанидино)- ( 15 2,4-триазол-5-ют) тиазолов, обладающих способностью блокировать действие гистамин-Н -рецептораСан- тагонисты гистамин-Н -рецептора), ингибировать секрецию кислоты, вход щей в состав желудочного сока, и ингибировать образование звы желудка, вызываемой алкоголем. Эти соединени могут быть полезны дл предотвраще- Н1ИЯ и лечени повьшенной желудочной кислотности и пептических зв.
; Целью изобретени вл етс полу- ч|ение новых производных 2(М-заме- щённых гуанидино)-4-(1,2,4-триазол- -5-ил)-тиазолов,, которые могут най- ,тй применение в медицине в качестве антагониста гистамина-Н-, а также обладающих новым видом активности дл р да арилтиазолов - способностью ин гибировать образование звы желудкг, вызывающей алкоголем.
Все значени температуры указаны в градусах Цельси . Спектры дерного магнитного резонанса (ЯМР) измерены дл растворов в дейтерированном хлот роформе .(CDCI3 ), дейтерированном метаноле (CDjO) или дейтерированном дйметилсульфоксйде (DMBO-df,) и положени пиков даны в пол х на ил ЛИОН в нисход щей области от тетра- метилсилана. Дл форм пиков примен ютс следующие сокращени : bS - широкий синглет; S - синглет; d - дублет; t - триплет; q - квартет; m - мультиплет,,
П р и -м е р 1. Этил-2-(1-н-гек- сил-3-гуанидина)тиазол-4-карбоксн- лат.
Смесь 1-(н-гексилгуанил) тиокар- б;|мида (4,09 г, 20 ммолъ), этилбром- эфира пировиноградной кислоты (4,09 21 ) и 200 мл этанола нагревают с обратным холодильником в течение 4 ч и охлаждают. Смесь концентрируют в вакууме до желтого твердого вещества, которое обраба1 ьшшот насьш1енным раствором кислого углекислого натри и экстрагируют хлороформом . Высушенные экстракты концентрируют в вакууме до оранжевого масла, которое отверждают посредством растирани с гексаном. После пере криста.плизации из смеси гексана
0 5
0 5 0
5
0
5
с этилацетатом получают г (62%) желтых кристаллов. Обработка маточных растворов дает дополнительно 1,20 г (20%) продукта. Пробу дл анализа получают перекристаллизац- ей из гексана с этилацетатом, температура плавлени 118-119 С.
Масс спектр (га/е) : 298 (); Н - тР (CDClj ) доли на 1 млнЛс/): 0.,6-1,8 (т, 14 Н); 3,2 (т, 2 Н) j 4,3 (q, 1 7 Hj, 2 Н); 7,03 (S, пга- рокий, 3 Н); 7,41 (5, 1 Н).
Вычислено,%: С 52,32| Н 7,43; N 18,78.
НайденоД: С 52,41; Н 7,55; N 18.36.
Пример 2. 2-(1-н-гексил-З- -гуанидино) тиазол-4-карбоновой кислоты гидразид.
Смесь 3,36 г (11,3 ммоль) этил- -2-(1-н-Гексил-З-гуанидино) тиазол- -4-карбоксш1ата и 6,5 мп (110 моль) 38%-ного гидразингидрата в 110 мл этанола нагревают с обратным холодильником в течение 24 ч. Добавл ют дополнительно 6,5 мл гидразингидрата и продолжают : нагревание еще 24 ч.. Полученную, смесь охлаждают, растворитель выпаривают в вакууме, остаточное бесцветное твердое вещество растирают в порошок с изопропанолом и фильтруют. Получают 2,32 г (78%) бесцветного порошка, Про(5у дл анализа получают перекристаллизацией из изопропанола, температура плавлени 136-137°С. Масс спектр (т/е): 284. (); Н-ЯМР (DMSO-d /CDsOD) доли на млн. (с/ ): 0,7-1,7 (т, 11 Н); 3,2 . (т, 2 Н); 7,31 (S, 1 Н).
Вычислено,%: С 46,45; Н 7,09; N 29,55.
C H oNgOS
Найдено,%г ,С 46,10; Н 7,18; N 29,93,
Пример 3. 2-(1-н-гексил-3- -гуанидино)-4-(3-метил-1Н-1,2,4-три- азол-5-ил) тиазол (I)/
Смесь 568 мг (2,0 ммоль) 2-(1-н- -гекси.п-3-гуанидино) тиазол-4-карбо- новой кислоты гидразида, 751 мг (МО моль) тиоацетамида в 20 мл н-бутанола нагревают с обратным холодильником в течение 48 ч. Охлажденную реакционную смесь концентрируют в вакууме и остаток хроматографируют на колонке с силикагелем, что дает 241 мг (39%) чистого триазола в виде
10
15
20
желтой губчатой массы, температура плавлени 207-209°С. Масс спектр (га/е): 307 (М ); Н - ЯМР (CDOD) доли на млн. (сГ): 0,7-1,8 (т, 11 Н); 2,43 (S, 3 Н); 3,3 (т, 2 Н); 7,22 (S, 1Н).
Вычислено, %: С 49,34; Н 7,01,- N 30,99.
С ,И-,5 0,5Н20
Найдено, %: С 49,42; Н 6,73; N 30,82.
Пример 4. 2-(1-н-гексил-3- гуанидино)-4-(3-амино-1Н-1,2,4-три- азол-5-ил) тиазол (11).
Смесь 852 мг (3,0 ммоль) 2-(1-н- -гексил-3-гуанидино)-тиазол-4-кар- боновой кислоты гидразида, 835 мг (4,5 ммоль) S-метилизотиуроний сульфата и 492 мг натри ацетата и 30 мл н-бутанола нагревают с обратным холодильником в течение 4 ч и охлаждают . Полученную смесь фильтруют, фильтрат концентрируют в вакууме и остаток хроматографируют дважды на колонках с силикагелем, сначала от- мьшают из адсорбента 85:15 хлороформом/метанолом , затем ацетоном, что дает 491 мг (53%) указанного в заголовке соединени в виде твердого жел- 30 того вещества, температура плавлени 210-211 с. Масс спектр (т/е) 308 (М); Н - ЯМР (CDjOD) доли на млн. (Ю: 0,7-1,9 (т, 11 Н); 3,2 (т, 2 Н); 7,13 (S, 1 Н)..35
Вычислено, N 36,34.
С jH joNgS
Найдено, %: N 36,03.40
Пример 5. Активность в отношении противодействи к гистами- ну-Н.
Ак тивность соединений по предла- гаемому изобретению, противодейству- 45 кщему гистамину-Hj, определ ют по следующей методике.
Морских свиной быстро умерщвл ют ударом по голове, удал ют сердце и правую артерию препарируют так, что- 50 бы она была свободной. Артерию подвешивают изометричес ки в тканевой ванне с регулируемой температурой (32i2°C;. Эта ванна (10 мл) содержит оксигемированный (95% 5% СО7) 55 буфер (рН 7,4) Кребса-Хензелейта. Оставл ют дл стабилизации примерно на 1 ч. За это врем тканевую ванну промывают несколько раз сильной стру25
q 46,73; Н 6,54;
С 46,63; Н 6,42;
0
5
0
0 5
0
5
0 5
ей жидкости. Отдельные сокращени , относ щиес к предсердию, прослеживают с помощю приспособлени , передающего смещение от усили , соединенного с кардиотахометром и регистрирующим полиграфом Грасса. После получени кривой, выражающей зависимость между дозой и ответной реакцией со стороны гистамина, ванну, содержащую каждое предсердие, промывают несколько раз сильной струей свежего буфера и предсердие привод т в равновесие с основными частотами. После возвращени к основной частоте, добавл ют испытуемые соединени при избранных окончательных концентраци х и снова определ ют кривую доза гистамина - ответна реакци . Определ ют отношение концентрации гистамина, требуемое дл получени половины максимального стимулировани в присутствии или отсутствии антагониста и вычисл ют константу 5 кажущейс диссоциации Н -рецептора антагониста р А. Результаты испытаний приведены в табл.2.
Пример 6.
Ингибирование образовани зв, вызываемых этанолом у крыс.
Противо звенную активность продуктов согласно изобретению также определ ют у крысы посредством проверки звы, вызьшанной этанолом. При этом испытании самцам крыс, зафиксированным всю ночь, дают лекарство (при 30 или 3 мг/кг) или воду путем приема через рот за 15 мин до приема через рот дозы абсолютного этанола (1,0 мл). Через 1 ч после этанольного вызова животных (по 8 в группе) убивают и исследуют желудок на наличие повреждений. Путем оперативного вмешательства вскрьша- ют желудок и у привратника желудка устанавливают замь1кающий гемостат. В желудок ввод т инъекцией 6 мл 4%- ного раствора формальдегида через желудо.чный зонд и дл запирани пищевода устанавливают второй замыкающий челюстат. Желудок извлекают, вскрывают вдоль наибсшьшей кривизны и исследуют на образование зв,
Система подсчета, примен ема дл определени количества повре зде- ний, вызыванных этанолом, приводитс в табл,1.
лее 2, могут присутствовать точечные повреждени
: 5 Повреждени с кровотечением
Дл каждой группы животных вычис- л ют индекс звы, как показано далее
Индекс звы - (сумма повреждений дл каждой группы)X(сумма числа зв в каждой )х(дол в группе, име г ца звы в любой степени развити ) .
Ннгибирование образовани зв, выраженной в %, вьпшсл ют так:
% ингибировани 100х(индекс з- вМ .у контрольных) - (индекс звы у пЬлучивших лекарство)} :(индекс звы у; контрольных) о
Результаты испытаний по цитозащи- те приведены в табл.2.
Таблица 2 Активность в отношении противодействие; к гистамину-Н и цитозащитна активность производных арилтиазола и циме- тидина
ог
TH-
7,0
7,2
7,8
6,4
1,21 0,90 0,8
1,0
21
66
О
Не активен
почтительно принимать лекарства через рот. Обычно соединени формулы (I) подлежат введению через рот при приблизительных дозировках в пределах
О,Г до 20 мг/кг веса тела субъекта, которого лечат в сутки, предпочтительно примерно от 0,2 до 2,5 мг/кг в сутки в единичной или разделенной на несколько частей дозах. Если желательно введение с лечебной целью, мину пищеварительньй тракт, то данные соединени можно давать в виде общих суточных доз в пределах около 0,1 и 1,0 мг/кг веса тела субъектанаход щегос на излечении.
Таким образом, полученные предлагаемым способом соединени обладают низкой степенью токсичности по отношению к человеку.
35
Форм у л а и 3 о б р ё т е н и
Способ получени производньгх арилтиазолов общей формулы (I)
V
40S
кгN jr- il HN NH2 H-CgH
45
tf.
ъг I
н
50
i
где R - метил или аминогруппа; отлич ающийс тем, что гидразид кислоты формулы
$
J-П
II
H-CeHia
1 H CONHNHg
1400508
подвергают взаимодействию с .тиоаце- 1,5 соответственно в среде бутанола тамидом или солью S-метилизотиуро- при температуре его кипени с-об- ни при мол рном соотношении Is55 - ратным холодильником.
Claims (1)
- • Форм ул а и з о б р е те н и яСпособ получения производных арилтиазопов общей формулы (I)Соединение, №АналогЦиметидинАнт мина-Н рА2 ~7~0 ~7,27,86,4 агонизм гистагОткос, рост на косом агареГ, 2?'0,900,8ЦитозащитаЕД5о (% защиты при30 мг (кг) , орально1,0 н-с6нйR - метил или л и ч а ю щ и где о т гидразид кислоты формулы аминогруппа;й с я тем, чтоНе активен conhnh2 подвергают взаимодействию с .тиоацетамидом или солью S-метилизотиурония при молярном соотношении 1:55 -1,5 соответственно в среде бутанола при температуре его кипения с-обратным холодильником.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/605,510 US4560690A (en) | 1984-04-30 | 1984-04-30 | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1400508A3 true SU1400508A3 (ru) | 1988-05-30 |
Family
ID=24423963
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU853884505A SU1380614A3 (ru) | 1984-04-30 | 1985-04-29 | Способ получени производных арилтиазолов или их хлористоводородных или бромистоводородных солей |
SU864027210A SU1400508A3 (ru) | 1984-04-30 | 1986-04-02 | Способ получени производных арилтиазолов |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU853884505A SU1380614A3 (ru) | 1984-04-30 | 1985-04-29 | Способ получени производных арилтиазолов или их хлористоводородных или бромистоводородных солей |
Country Status (26)
Country | Link |
---|---|
US (1) | US4560690A (ru) |
EP (1) | EP0161841B1 (ru) |
JP (1) | JPS60239474A (ru) |
KR (1) | KR870000925B1 (ru) |
AR (1) | AR241784A1 (ru) |
AU (1) | AU554271B2 (ru) |
CA (1) | CA1262352A (ru) |
CS (2) | CS248741B2 (ru) |
DD (1) | DD233374A5 (ru) |
DE (1) | DE3571618D1 (ru) |
DK (1) | DK165693C (ru) |
EG (1) | EG17391A (ru) |
ES (2) | ES8605511A1 (ru) |
FI (1) | FI81096C (ru) |
GR (1) | GR851020B (ru) |
HU (1) | HU198300B (ru) |
IL (1) | IL75038A (ru) |
IN (1) | IN165501B (ru) |
NO (1) | NO164097C (ru) |
NZ (1) | NZ211909A (ru) |
PH (1) | PH21824A (ru) |
PL (2) | PL145213B1 (ru) |
PT (1) | PT80361B (ru) |
SU (2) | SU1380614A3 (ru) |
YU (2) | YU43977B (ru) |
ZA (1) | ZA853161B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2487130C2 (ru) * | 2005-09-22 | 2013-07-10 | Абботт Лаборэтриз | Производные бензотиазолциклобутиламина в качестве лигандов гистаминовых h3-рецепторов, фармацевтическая композиция на их основе, способ селективной модуляции эффектов гистаминовых h3-рецепторов и способ лечения состояния или нарушения, модулируемого гистаминовыми h3-рецепторами |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986003203A1 (en) * | 1984-11-22 | 1986-06-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylthiazole derivatives |
US5001138B1 (en) * | 1985-02-04 | 1998-01-20 | Bayer Agrochem Kk | Heterocyclic compounds |
ATE67493T1 (de) | 1985-02-04 | 1991-10-15 | Bayer Agrochem Kk | Heterocyclische verbindungen. |
ES2031514T3 (es) * | 1986-08-29 | 1992-12-16 | Pfizer Inc. | 2-guanidino-4-ariltiazoles para el tratamiento de ulceras pepticas. |
WO1988003141A1 (en) * | 1986-10-29 | 1988-05-05 | Pfizer Inc. | Processes for 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and analogs |
DE3750023T2 (de) * | 1986-10-29 | 1994-09-29 | Pfizer | Verfahren zur Herstellung von 2-(1-Pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)Thiazol und dessen kristallinisches Dihydrochlorid-Trihydrat. |
US4997949A (en) * | 1986-10-29 | 1991-03-05 | Pfizer Inc. | Crystalline 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl) thiazole dihydrochloride trihydrate |
DE3715704A1 (de) * | 1987-05-12 | 1988-11-24 | Bayer Ag | Ss-fluoracyl-ss-halogenvinylalkylether |
ES2030974T3 (es) * | 1988-07-21 | 1992-11-16 | Pfizer Inc. | Proceso de preparado de sustitutos de guaniltioureas. |
IL91152A0 (en) * | 1988-08-15 | 1990-03-19 | Fujisawa Pharmaceutical Co | Furylthiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
WO1990002127A1 (en) * | 1988-08-30 | 1990-03-08 | Pfizer Inc. | Hemiphosphate hemihydrate of 2-(1-pentyl-3-guanidino-4-imidazolyl)thiazole |
GB8903592D0 (en) * | 1989-02-16 | 1989-04-05 | Boots Co Plc | Therapeutic agents |
IL95548A0 (en) * | 1989-09-15 | 1991-06-30 | Fujisawa Pharmaceutical Co | Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same |
US4985402A (en) * | 1990-04-25 | 1991-01-15 | International Flavors & Fragrances Inc. | 2-Methyl-1-nitrilo-2-methyl -1-hydroxylamino-3-(methoxyphenyl) propane, organoleptic uses thereof and processes for preparing same |
US5387656A (en) * | 1990-07-23 | 1995-02-07 | Alliedsignal Inc. | Substituted cyanoguanidines as curing agents for epoxy resins |
US5622979A (en) * | 1990-12-24 | 1997-04-22 | Ciba-Geigy Corporation | Thiangazole, its preparation, compositions and use thereof |
EP0564479A1 (en) * | 1990-12-24 | 1993-10-13 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Thiangazole, its preparation, compositions and use thereof |
US5387597A (en) * | 1991-02-25 | 1995-02-07 | Pfizer Inc. | Hemiphosphate hemihydrate of 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole |
EP0575614A1 (en) * | 1991-03-13 | 1993-12-29 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives |
AU6436394A (en) * | 1993-06-15 | 1995-01-03 | Pfizer Inc. | H2-antagonists as immune stimulants in bacterial infections of cattle or swine |
DE69414708T2 (de) * | 1993-08-24 | 1999-04-15 | Medivir Ab | Verbindungen und methoden zur inhibition von hiv und verwandten viren |
DE19523658A1 (de) * | 1995-06-29 | 1997-01-02 | Bayer Ag | Substituierte N-Methylenthioharnstoffe |
SI0928793T1 (en) * | 1998-01-02 | 2002-10-31 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
DE102004008141A1 (de) * | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
US8895564B2 (en) | 2010-12-02 | 2014-11-25 | Nihon University | Biguanide derivative compound |
EP4196793A1 (en) | 2020-08-11 | 2023-06-21 | Université de Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2455807A (en) * | 1945-09-11 | 1948-12-07 | American Cyanamid Co | Preparation of substituted cyanoguanidine |
IL49528A (en) * | 1975-05-21 | 1980-11-30 | Smith Kline French Lab | Imidazolyl(or thiazolyl)methylthio(or butyl)guanidine or thiourea derivatives,their preparation and pharmaceutical compositions comprising them |
JPS54132566A (en) * | 1978-01-18 | 1979-10-15 | Ici Ltd | Guanidine derivative*its manufacture and secretion controlling pharmaceutical composition containing it |
JPS6056143B2 (ja) * | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
GR71929B (ru) * | 1979-11-13 | 1983-08-19 | Ici Ltd | |
US4374843A (en) * | 1980-10-14 | 1983-02-22 | Pfizer Inc. | 2-Guanidino-4-heteroarylthiazoles |
US4435396A (en) * | 1982-05-10 | 1984-03-06 | Pfizer Inc. | Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor |
-
1984
- 1984-04-30 US US06/605,510 patent/US4560690A/en not_active Expired - Lifetime
-
1985
- 1985-03-22 IN IN244/DEL/85A patent/IN165501B/en unknown
- 1985-04-24 EP EP85302844A patent/EP0161841B1/en not_active Expired
- 1985-04-24 DE DE8585302844T patent/DE3571618D1/de not_active Expired
- 1985-04-25 CS CS853042A patent/CS248741B2/cs not_active IP Right Cessation
- 1985-04-25 CS CS857163A patent/CS248750B2/cs not_active IP Right Cessation
- 1985-04-26 DD DD85275638A patent/DD233374A5/de not_active IP Right Cessation
- 1985-04-26 PL PL1985253107A patent/PL145213B1/pl unknown
- 1985-04-26 PL PL1985257845A patent/PL146070B1/pl unknown
- 1985-04-26 CA CA000480150A patent/CA1262352A/en not_active Expired
- 1985-04-26 PT PT80361A patent/PT80361B/pt not_active IP Right Cessation
- 1985-04-26 GR GR851020A patent/GR851020B/el unknown
- 1985-04-26 NZ NZ211909A patent/NZ211909A/en unknown
- 1985-04-28 EG EG268/85A patent/EG17391A/xx active
- 1985-04-29 AR AR85300218A patent/AR241784A1/es active
- 1985-04-29 IL IL75038A patent/IL75038A/xx not_active IP Right Cessation
- 1985-04-29 AU AU41790/85A patent/AU554271B2/en not_active Ceased
- 1985-04-29 HU HU851646A patent/HU198300B/hu not_active IP Right Cessation
- 1985-04-29 SU SU853884505A patent/SU1380614A3/ru active
- 1985-04-29 KR KR1019850002872A patent/KR870000925B1/ko not_active IP Right Cessation
- 1985-04-29 YU YU723/85A patent/YU43977B/xx unknown
- 1985-04-29 PH PH32200A patent/PH21824A/en unknown
- 1985-04-29 NO NO851695A patent/NO164097C/no unknown
- 1985-04-29 DK DK190885A patent/DK165693C/da not_active IP Right Cessation
- 1985-04-29 ES ES542703A patent/ES8605511A1/es not_active Expired
- 1985-04-29 FI FI851683A patent/FI81096C/fi not_active IP Right Cessation
- 1985-04-29 ZA ZA853161A patent/ZA853161B/xx unknown
- 1985-04-30 JP JP60093524A patent/JPS60239474A/ja active Granted
- 1985-10-21 ES ES548073A patent/ES8606336A1/es not_active Expired
-
1986
- 1986-04-02 SU SU864027210A patent/SU1400508A3/ru active
-
1987
- 1987-06-18 YU YU1145/87A patent/YU44632B/xx unknown
Non-Patent Citations (1)
Title |
---|
Обща органическа хими , т.8 Азотсодержащие гетероциклы, М.: Хими , 1985, с.483-485. Патент US № 4374843,кл., опублик. 1983. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2487130C2 (ru) * | 2005-09-22 | 2013-07-10 | Абботт Лаборэтриз | Производные бензотиазолциклобутиламина в качестве лигандов гистаминовых h3-рецепторов, фармацевтическая композиция на их основе, способ селективной модуляции эффектов гистаминовых h3-рецепторов и способ лечения состояния или нарушения, модулируемого гистаминовыми h3-рецепторами |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1400508A3 (ru) | Способ получени производных арилтиазолов | |
FI78695B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-diaminocyklobuten-3,4-dionderivat. | |
JPH0220639B2 (ru) | ||
CH626883A5 (ru) | ||
FI73209C (fi) | Foerfarande foer framstaellning av nya imidazolylfenylamidiner, vilka har histamin h2-reseptorantagonist-aktivitet, som inhiberar utsoendring av magsyra. | |
WO1999062892A1 (en) | Aminoazole compounds | |
NZ188770A (en) | Thiazolinylguanidine derivatives and pharmaceutical compositions | |
US4522943A (en) | Chemical compounds | |
EP0099122B1 (en) | Compositions comprising pepstatin and an histamine h2-receptor antagonist having an enhanced antiulcer activity | |
NO781572L (no) | Fremgangsmaate for fremstilling av bisamidiner | |
US4666932A (en) | Formamidine derivatives and pharmaceutical use | |
US4649150A (en) | Antiulcerogenic amidine derivatives of 2-substituted 4-phenylimidazole | |
US4503051A (en) | Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use | |
KR860000103B1 (ko) | 3'-치환-5'-(2-아미노-4-피리딜)-1', 2', 4'-트리아졸류의 제조 방법 | |
GB1598628A (en) | Guanidine derivatives | |
US4539316A (en) | Pyridine derivatives of 1,2-diaminocyclobutene-3,4-diones | |
SU791241A3 (ru) | Способ получени производных 4,5,6,7-тетрагидроимидазо 4,5-с пиридина | |
EP0252422A2 (en) | Pyridazinone derivatives and salts thereof | |
US4772704A (en) | 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity | |
CS241141B2 (en) | Method of ethendiamine and guanidine derivatives production | |
US4607105A (en) | 3-cyclobutene-1,2-dione intermediates | |
EP0030835A1 (en) | Derivatives of 2-substituted-6-phenyl-3(2H)pyridazinone, their production and pharmaceutical compositions containing them | |
KR810000355B1 (ko) | 아미노 알킬푸란 유도체의 제조방법 | |
GB2192884A (en) | Substituted ethanediimidamides | |
DK149952B (da) | Analogifremgangsmaade til fremstilling af et aminoalkylfuranderivat |